Research comparison
AOD-9604 vs Semaglutide
Side-by-side comparison of research status, mechanisms, pharmacokinetics, and administration routes.
AOD-9604 is a modified fragment of human growth hormone (hGH 177-191) that retains the lipolytic properties of GH without its anabolic or diabetogenic effects. It stimulates lipolysis through β3-adrenergic receptor pathways and inhibits lipogenesis. Phase 3 trials for obesity were conducted; it has since been investigated for osteoarthritis through cartilage repair properties.
Research Status
phase3
Half-Life
~30 minutes
Molecular Formula
—
Molecular Weight
—
CAS Number
221231-10-3
Research Categories
Fat Loss & Metabolic
Routes of Administration
Semaglutide is a long-acting GLP-1 receptor agonist approved for type 2 diabetes (Ozempic, Rybelsus) and obesity (Wegovy). By mimicking the incretin hormone GLP-1, it enhances glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite via central hypothalamic pathways. Landmark trials demonstrate up to 15–17% body weight reduction and significant cardiovascular mortality benefit.
Research Status
FDA Approved
Half-Life
~1 week (allows once-weekly dosing)
Molecular Formula
—
Molecular Weight
—
CAS Number
910463-68-2
Research Categories
GLP-1 & Metabolic Hormones, Fat Loss & Metabolic, Cardiovascular
Routes of Administration
Full mechanism comparison
Mechanism of action, pharmacokinetics, and research findings comparison available on the Researcher plan.
Unlock full comparison →Related comparisons